Format

Send to

Choose Destination
Crit Rev Oncol Hematol. 2018 Nov;131:30-34. doi: 10.1016/j.critrevonc.2018.08.009. Epub 2018 Aug 27.

Criteria for eligibility to cisplatin in the curative treatment of head and neck cancer: Consensus opinion from a panel of experts.

Author information

1
Instituto do Câncer do Estado de São Paulo, São Paulo, Brazil. Electronic address: gilberto.castro@usp.br.
2
Hospital Nossa Senhora da Conceição, Porto Alegre, Brazil.
3
Lenitudes Medical Center & Research, Santa Maria da Feira, Portugal.
4
DOM Oncologia, Divinópolis, Brazil.
5
Hospital do Câncer de Barretos, Barretos, Brazil.
6
AC Camargo Cancer Center, São Paulo, Brazil.
7
Instituto Nacional de Câncer, Rio de Janeiro, Brazil.
8
Clínica CLION, Grupo CAM, Salvador, Brazil.
9
AC Camargo Cancer Center, São Paulo, Brazil; Hospital Amaral Carvalho, Jaú, Brazil.
10
Centro Paulista de Oncologia, São Paulo, Brazil; Hospital Israelita Albert Einstein, São Paulo, Brazil.

Abstract

Squamous-cell carcinoma of the head and neck (SCCHN) is an important problem in Brazil, where epidemiological and socioeconomic features often create barriers to the implementation of combined modalities with curative potential. Cisplatin improves the efficacy of radiotherapy in the adjuvant treatment of localized SCCHN and in the definitive therapy of locally advanced disease. However, the addition of high-dose cisplatin to radiotherapy increases treatment toxicity and is not always warranted. A panel of experts convened in Sao Paulo, Brazil, for discussions and recommendations regarding the use of high-dose cisplatin in combination with radiotherapy in SCCHN. In addition to discussing their professional experience, panel members used the current literature to provide evidence-based, practical recommendations regarding sociodemographic or medical criteria that may preclude safe administration of cisplatin. It is hoped that the application of these recommendations in clinical practice may improve therapeutic results in Brazil and other countries with similar health-care environments.

KEYWORDS:

Cetuximab; Cisplatin; Drug therapy; Head and neck neoplasms; Platinum analogs; Radiotherapy

[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center